Readystate Asset Management’s Vaxcyte PCVX Stock Holding History

Readystate Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.07M	Buy	156,090 +120,000	+333%	+$6.52M	0.31%	73
2026 Q1	$2.1M	Sell	36,090 -95,547	-73%	-$5.19M	0.09%	140
2025 Q4	$6.07M	Buy	+131,637	New	+$5.89M	0.25%	75
2025 Q3	–	Sell	-35,819	Closed	-$1.16M	–	607
2025 Q2	$1.16M	Buy	+35,819	New	+$1.17M	0.04%	196
2023 Q4	–	Sell	-58,472	Closed	-$2.98M	–	694
2023 Q3	$2.98M	Buy	58,472 +2,952	+5%	+$146K	0.15%	160
2023 Q2	$2.77M	Buy	+55,520	New	+$2.63M	0.21%	111

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Readystate Asset Management's PCVX Position: Q2 2026 in Review

Readystate Asset Management increased its Vaxcyte (PCVX) stake by 333% in Q2 2026, buying an estimated $6.52M and bringing the position to 156,090 shares worth $9.07M. The position accounts for 0.31% of the portfolio, ranked #73.

Readystate Asset Management first reported a position in PCVX in Q2 2023 and has held it in 6 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Readystate Asset Management held 156,090 shares of Vaxcyte worth $9.07M as of Q2 2026.
Readystate Asset Management bought 120,000 Vaxcyte shares in Q2 2026, an estimated $6.52M.
Vaxcyte made up 0.31% of Readystate Asset Management's portfolio in Q2 2026, its #73 holding.
Readystate Asset Management first reported a position in Vaxcyte in Q2 2023 and has held it in 6 quarters since.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Readystate Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.